Direct and indirect effects of cytomegalovirus: can we prevent them?

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 28, Issue 1, 2010, Pages 1-5

  Razonable, Raymund ^a  

^a William J von Liebig Transplant Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; GANCICLOVIR; OKT 3; PLACEBO; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ABDOMINAL PAIN; ACUTE GRAFT REJECTION; ANTIVIRAL THERAPY; ARTICLE; BACTERIAL INFECTION; BLEEDING; BONE MARROW SUPPRESSION; BRONCHIOLITIS OBLITERANS; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC GRAFT REJECTION; CLINICAL TRIAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DIARRHEA; FEVER; FIBROSING ALVEOLITIS; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TRACT; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS; HEPATITIS C; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LYMPHOPROLIFERATIVE DISEASE; MYCOSIS; MYOCARDITIS; NEPHRITIS; NOCARDIOSIS; PANCREATITIS; PNEUMONIA; POLYMERASE CHAIN REACTION; PROPHYLAXIS; RETINITIS; RISK FACTOR; T LYMPHOCYTE; THROMBOSIS; VASCULAR DISEASE; VIRUS LOAD;

ANTIVIRAL AGENTS; BONE MARROW DISEASES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DIGESTIVE SYSTEM DISEASES; FEVER; HUMANS; IMMUNOCOMPROMISED HOST; MYOCARDITIS; NEPHRITIS; OPPORTUNISTIC INFECTIONS; ORGAN TRANSPLANTATION; PNEUMONIA, VIRAL; POLYMERASE CHAIN REACTION; POSTOPERATIVE COMPLICATIONS; PREMEDICATION; RISK FACTORS; SUPERINFECTION; VIRUS ACTIVATION; VIRUS REPLICATION;

EID: 73549123447     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/j.eimc.2009.07.008     Document Type: Article

References (58)

1. Razonable R.R. Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients. Am J Health Syst Pharm 62 8 Suppl 1 (2005) S7-S13
2. Razonable R.R., and Emery V.C. Management of CMV infection and disease in transplant patients. 27-29 February 2004. Herpes 11 (2004) 77-86
3. Ljungman P., Griffiths P., and Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 34 (2002) 1094-1097
4. Arthurs S.K., Eid A.J., Pedersen R.A., Dierkhising R.A., Kremers W.K., Patel R., et al. Delayed-onset primary cytomegalovirus disease after liver transplantation. Liver Transpl 13 (2007) 1703-1709
5. Arthurs S.K., Eid A.J., Pedersen R.A., Kremers W.K., Cosio F.G., Patel R., et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 46 (2008) 840-846
6. Gane E., Saliba F., Valdecasas G.J., O'Grady J., Pescovitz M.D., Lyman S., et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. Lancet 350 (1997) 1729-1733
7. Kijpittayarit S., Deziel P., Eid A.J., and Razonable R.R. Primary cytomegalovirus disease after five years of antiviral prophylaxis. Transplantation 81 (2006) 137-138
8. Lowance D., Neumayer H.H., Legendre C.M., Squifflet J.P., Kovarik J., Brennan P.J., et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 340 (1999) 1462-1470
9. Paya C., Humar A., Dominguez E., Washburn K., Blumberg E., Alexander B., et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 4 (2004) 611-620
10. Boeckh M., Fries B., and Nichols W.G. Recent advances in the prevention of CMV infection and disease after hematopoietic stem cell transplantation. Pediatr Transplant 8 Suppl 5 (2004) 19-27
11. Boeckh M., and Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 113 (2009) 5711-5719
12. Nichols W.G., and Boeckh M. Recent advances in the therapy and prevention of CMV infections. J Clin Virol 16 (2000) 25-40
13. Eid A.J., Bakri S.J., Kijpittayarit S., and Razonable R.R. Clinical features and outcomes of cytomegalovirus retinitis after transplantation. Transpl Infect Dis 10 (2008) 13-18
14. Cytomegalovirus. Am J Transplant 2004;4(Suppl 10):51-8.
15. Boeckh M., Nichols W.G., Papanicolaou G., Rubin R., Wingard J.R., and Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 9 (2003) 543-558
16. Peleg A.Y., Husain S., Kwak E.J., Silveira F.P., Ndirangu M., Tran J., et al. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis 44 (2007) 204-212
17. Razonable R.R., Rivero A., Rodriguez A., Wilson J., Daniels J., Jenkins G., et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis 184 (2001) 1461-1464
18. Cervera C., Lozano F., Saval N., Gimferrer I., Ibañez A., Suárez B., et al. The influence of innate immunity gene receptors polymorphisms in renal transplant infections. Transplantation 83 (2007) 1493-1500
19. Kijpittayarit S., Eid A.J., Brown R.A., Paya C.V., and Razonable R.R. Relationship between Toll-like receptor 2 polymorphism and cytomegalovirus disease after liver transplantation. Clin Infect Dis 44 (2007) 1315-1320
20. Kumar D., Chernenko S., Moussa G., Cobos I., Manuel O., Preiksaitis J., et al. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant 9 (2009) 1214-1222
21. Razonable R.R., van Cruijsen H., Brown R.A., Wilson J.A., Harmsen W.S., Wiesner R.H., et al. Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir. J Infect Dis 187 (2003) 1801-1808
22. Hodson E.M., Barclay P.G., Craig J.C., Jones C., Kable K., Strippoli G.F., et al. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev (2005) CD003774
23. Hodson E.M., Craig J.C., Strippoli G.F., and Webster A.C. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev (2008) CD003774
24. Kalil A.C., Levitsky J., Lyden E., Stoner J., and Freifeld A.G. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 143 (2005) 870-880
25. Khoury J.A., Storch G.A., Bohl D.L., Schuessler R.M., Torrence S.M., Lockwood M., et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 6 (2006) 2134-2143
26. Reischig T., Jindra P., Hes O., Svecova M., Klaboch J., and Treska V. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant 8 (2008) 69-77
27. Small L.N., Lau J., and Snydman D.R. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies. Clin Infect Dis 43 (2006) 869-880
28. Paya C.V., Wilson J.A., Espy M.J., Sia I.G., DeBernardi M.J., Smith T.F., et al. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial. J Infect Dis 185 (2002) 854-860
29. Razonable R.R., Paya C.V., and Smith T.F. Role of the laboratory in diagnosis and management of cytomegalovirus infection in hematopoietic stem cell and solid-organ transplant recipients. J Clin Microbiol 40 (2002) 746-752
30. Torre-Cisneros J., Caston-Osorio J., Calvo C.M., et al. Impacto de la carga vírica inicial de citomegalovirus sobre la eficacia del tratamiento anticipado con ganciclovir en receptores de trasplante de progenitores hematopoyéticos. Enfermedades Infecciosas y Microbiologica Clinica (2009) 10.1016/j.eimc.2009.01.010
31. Asberg A., Humar A., Rollag H., Jardine A.G., Mouas H., Pescovitz M.D., et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 7 (2007) 2106-2113
32. Sia I.G., Wilson J.A., Groettum C.M., Espy M.J., Smith T.F., and Paya C.V. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J Infect Dis 181 (2000) 717-720
33. Humar A, Lebranchu Y, Vincenti F, Punch J, Abramowicz D, Blumberg E. The Impact Study: valganciclovir prophylaxis for until 200 days post-transplant in high risk kidney recipients substantially reduces the incidence of CMV disease. In: Proceedings from the American Transplant Congress; May 30-June 3, 2009; Boston, MA Abstract 201 2009; Boston, MA.: American Transplant Congress; 2009.
34. Cummins N.W., Deziel P.J., Abraham R.S., and Razonable R.R. Deficiency of cytomegalovirus (CMV)-specific CD8+ T cells in patients presenting with late-onset CMV disease several years after transplantation. Transpl Infect Dis 11 (2009) 20-27
35. Limaye A.P., Bakthavatsalam R., Kim H.W., Randolph S.E., Halldorson J.B., Healey P.J., et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 81 (2006) 1645-1652
36. Boeckh M., and Nichols W.G. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 103 (2004) 2003-2008
37. Nichols W.G., Corey L., Gooley T., Davis C., and Boeckh M. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis 185 (2002) 273-282
38. Boeckh M., and Nichols W.G. Immunosuppressive effects of beta-herpesviruses. Herpes 10 (2003) 12-16
39. Helantera I., Koskinen P., Finne P., Loginov R., Kyllönen L., Salmela K., et al. Persistent cytomegalovirus infection in kidney allografts is associated with inferior graft function and survival. Transpl Int 19 (2006) 893-900
40. Reischig T., Jindra P., Hes O., Bouda M., Kormunda S., and Treska V. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis. Transplantation 87 (2009) 436-444
41. Munoz-Price L.S., Slifkin M., Ruthazer R., Poutsiaka D.D., Hadley S., Freeman R., et al. The clinical impact of ganciclovir prophylaxis on the occurrence of bacteremia in orthotopic liver transplant recipients. Clin Infect Dis 39 (2004) 1293-1299
42. Walker R.C., Marshall W.F., Strickler J.G., Wiesner R.H., Velosa J.A., Habermann T.M., et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 20 (1995) 1346-1353
43. Razonable R.R., Rivero A., Brown R.A., Hart G.D., Espy M.J., van Cruijsen H., et al. Detection of simultaneous beta-herpesvirus infections in clinical syndromes due to defined cytomegalovirus infection. Clin Transplant 17 (2003) 114-120
44. Burak K.W., Kremers W.K., Batts K.P., Wiesner R.H., Rosen C.B., Razonable R.R., et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 8 (2002) 362-369
45. Razonable R.R., Burak K.W., van Cruijsen H., Brown R.A., Charlton M.R., Smith T.F., et al. The pathogenesis of hepatitis C virus is influenced by cytomegalovirus. Clin Infect Dis 35 (2002) 974-981
46. Thomas L.D., Milstone A.P., Miller G.G., Loyd J.E., and Stephen Dummer J. Long-term outcomes of cytomegalovirus infection and disease after lung or heart-lung transplantation with a delayed ganciclovir regimen. Clin Transplant (2009)
47. Valentine V.G., Weill D., Gupta M.R., Raper B., Laplace S.G., Lombard G.A., et al. Ganciclovir for cytomegalovirus: a call for indefinite prophylaxis in lung transplantation. J Heart Lung Transplant 27 (2008) 875-881
48. Fearon W.F., Potena L., Hirohata A., Sakurai R., Yamasaki M., Luikart H., et al. Changes in coronary arterial dimensions early after cardiac transplantation. Transplantation 83 (2007) 700-705
49. Ozdemir F.N., Akgul A., Altunoglu A., Bilgic A., Arat Z., and Haberal M. The association between cytomegalovirus infection and atherosclerotic events in renal transplant recipients. Transplant Proc 39 (2007) 990-992
50. Rodrigo E., Fernandez-Fresnedo G., Valero R., Ruiz J.C., Piñera C., Palomar R., et al. New-onset diabetes after kidney transplantation: risk factors. J Am Soc Nephrol 17 12 Suppl 3 (2006) S291-S295
51. Ljungman P., Brand R., Einsele H., Frassoni F., Niederwieser D., and Cordonnier C. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood 102 (2003) 4255-4260
52. Kliem V., Fricke L., Wollbrink T., Burg M., Radermacher J., and Rohde F. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant 8 (2008) 975-983
53. Reischig T., Jindra P., Mares J., Cechura M., Svecová M., Hes O., et al. Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection. Transplantation 79 (2005) 317-324
54. Slifkin M., Ruthazer R., Freeman R., Bloom J., Fitzmaurice S., Fairchild R., et al. Impact of cytomegalovirus prophylaxis on rejection following orthotopic liver transplantation. Liver Transpl 11 (2005) 1597-1602
55. Potena L., Holweg C.T., Chin C., Luikart H., Weisshaar D., Narasimhan B., et al. Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection. Transplantation 82 (2006) 398-405
56. Tu W., Potena L., Stepick-Biek P., Liu L., Dionis K.Y., Luikart H., et al. T-cell immunity to subclinical cytomegalovirus infection reduces cardiac allograft disease. Circulation 114 (2006) 1608-1615
57. Asberg A., Humar A., Jardine A.G., Rollag H., Pescovitz M.D., Mouas H., et al. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant 9 (2009) 1205-1213
58. Pang X.L., Fox J.D., Fenton J.M., Miller G.G., Caliendo A.M., and Preiksaitis J.K. Interlaboratory comparison of cytomegalovirus viral load assays. Am J Transplant 9 (2009) 258-268